- Home
- GERN vs SEB Comparison
GERN vs SEB Comparison
Compare GERN & SEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GERN
- SEB
- Stock Information
- Founded
- GERN 1990
- SEB 1918
- Country
- GERN United States
- SEB United States
- Employees
- GERN N/A
- SEB N/A
- Industry
- GERN Biotechnology: Pharmaceutical Preparations
- SEB Farming/Seeds/Milling
- Sector
- GERN Health Care
- SEB Industrials
- Exchange
- GERN Nasdaq
- SEB Nasdaq
- Market Cap
- GERN 2.5B
- SEB N/A
- IPO Year
- GERN 1996
- SEB N/A
- Fundamental
- Price
- GERN $4.06
- SEB $3,058.07
- Analyst Decision
- GERN Strong Buy
- SEB
- Analyst Count
- GERN 9
- SEB 0
- Target Price
- GERN $6.83
- SEB N/A
- AVG Volume (30 Days)
- GERN 7.9M
- SEB 2.8K
- Earning Date
- GERN 11-07-2024
- SEB 10-28-2024
- Dividend Yield
- GERN N/A
- SEB 0.30%
- EPS Growth
- GERN N/A
- SEB N/A
- EPS
- GERN N/A
- SEB 266.92
- Revenue
- GERN $1,373,000.00
- SEB $9,070,000,000.00
- Revenue This Year
- GERN $23,693.67
- SEB N/A
- Revenue Next Year
- GERN $401.91
- SEB N/A
- P/E Ratio
- GERN N/A
- SEB $11.32
- Revenue Growth
- GERN 205.11
- SEB N/A
- 52 Week Low
- GERN $1.64
- SEB $2,955.33
- 52 Week High
- GERN $5.34
- SEB $3,796.00
- Technical
- Relative Strength Index (RSI)
- GERN 39.25
- SEB 44.34
- Support Level
- GERN $4.11
- SEB $2,988.02
- Resistance Level
- GERN $4.37
- SEB $3,115.00
- Average True Range (ATR)
- GERN 0.17
- SEB 64.76
- MACD
- GERN -0.03
- SEB -11.68
- Stochastic Oscillator
- GERN 20.27
- SEB 36.10
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.